BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 23065524)

  • 21. Posttransplant lymphoproliferative disorder: a pictorial review.
    Burney K; Bradley M; Buckley A; Lyburn I; Rye A; Hopkins R
    Australas Radiol; 2006 Oct; 50(5):412-8. PubMed ID: 16981935
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Epstein-Barr virus DNAemia in Iranian liver transplant recipients and assessment of its variation in posttransplant lymphproliferative disorder patients by quantitative polymerase chain reaction assay.
    Jamalidoust M; Geramizadeh B; Pouladfar G; Namayandeh M; Asaie S; Aliabadi N; Nikeghbalian S; Ziyaeyan M
    Exp Clin Transplant; 2015 Apr; 13 Suppl 1():306-11. PubMed ID: 25894179
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Presentation and early detection of post-transplant lymphoproliferative disorder after solid organ transplantation.
    Bakker NA; van Imhoff GW; Verschuuren EA; van Son WJ
    Transpl Int; 2007 Mar; 20(3):207-18. PubMed ID: 17291214
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The usefulness of (18)F-FDG PET/CT for assessing methotrexate-associated lymphoproliferative disorder (MTX-LPD).
    Watanabe S; Manabe O; Hirata K; Oyama-Manabe N; Hattori N; Kikuchi Y; Kobayashi K; Toyonaga T; Tamaki N
    BMC Cancer; 2016 Aug; 16():635. PubMed ID: 27528380
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The role of fluorodeoxyglucose-positron emission tomography/computed tomography in differentiating between benign and malignant adrenal lesions.
    Ozcan Kara P; Kara T; Kara Gedik G; Kara F; Sahin O; Ceylan Gunay E; Sari O
    Nucl Med Commun; 2011 Feb; 32(2):106-12. PubMed ID: 21085046
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [The application of 18F-fluorodeoxyglucose positron emission tomography in the diagnosis and staging of lung cancer].
    Xu HF; Liu Y; Zhang JH; Zhou RS; Zhou FH; Yuan MH
    Zhonghua Jie He He Hu Xi Za Zhi; 2005 Feb; 28(2):108-11. PubMed ID: 15854393
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Positron emission tomography with f18-fluorodeoxyglucose in the staging and preoperative evaluation of malignant pleural mesothelioma.
    Schneider DB; Clary-Macy C; Challa S; Sasse KC; Merrick SH; Hawkins R; Caputo G; Jablons D
    J Thorac Cardiovasc Surg; 2000 Jul; 120(1):128-33. PubMed ID: 10884665
    [TBL] [Abstract][Full Text] [Related]  

  • 28. (18)F-FDG PET/CT in the management of patients with post-transplant lymphoproliferative disorder.
    Takehana CS; Twist CJ; Mosci C; Quon A; Mittra E; Iagaru A
    Nucl Med Commun; 2014 Mar; 35(3):276-81. PubMed ID: 24296883
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Post transplant lymphoproliferative disease in pediatric solid organ transplant patients: a possible role for [18F]-FDG-PET(/CT) in initial staging and therapy monitoring.
    von Falck C; Maecker B; Schirg E; Boerner AR; Knapp WH; Klein C; Galanski M
    Eur J Radiol; 2007 Sep; 63(3):427-35. PubMed ID: 17293073
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Adrenal masses: the value of additional fluorodeoxyglucose-positron emission tomography/computed tomography (FDG-PET/CT) in differentiating between benign and malignant lesions.
    Okada M; Shimono T; Komeya Y; Ando R; Kagawa Y; Katsube T; Kuwabara M; Yagyu Y; Kumano S; Imaoka I; Tsuchiya N; Ashikaga R; Hosono M; Murakami T
    Ann Nucl Med; 2009 Jun; 23(4):349-54. PubMed ID: 19340526
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Posttransplant lymphoproliferative disorder with lung involvement in a renal transplant recipient.
    Mirza EI; Mutluay R; Suyani E; Okyay GU; Akyurek N; Aki SZ; Derici U; Arinsoy T
    Exp Clin Transplant; 2011 Dec; 9(6):425-8. PubMed ID: 22142053
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [F-18]fluorodeoxyglucose positron emission tomography and positron emission tomography: computed tomography in recurrent and metastatic cholangiocarcinoma.
    Jadvar H; Henderson RW; Conti PS
    J Comput Assist Tomogr; 2007; 31(2):223-8. PubMed ID: 17414758
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Diagnostic performance of FDG-PET/CT of post-transplant lymphoproliferative disorder and factors affecting diagnostic yield.
    Montes de Jesus FM; Kwee TC; Kahle XU; Nijland M; van Meerten T; Huls G; Dierckx RAJO; Rosati S; Diepstra A; van der Bij W; Verschuuren EAM; Glaudemans AWJM; Noordzij W
    Eur J Nucl Med Mol Imaging; 2020 Mar; 47(3):529-536. PubMed ID: 31444510
    [TBL] [Abstract][Full Text] [Related]  

  • 34. RELIABILITY OF POSITRON EMISSION TOMOGRAPHY-COMPUTED TOMOGRAPHY IN EVALUATION OF TESTICULAR CARCINOMA PATIENTS.
    Nikoletić K; Mihailović J; Matovina E; Žeravica R; Srbovan D
    Med Pregl; 2015; 68(3-4):109-15. PubMed ID: 26214990
    [TBL] [Abstract][Full Text] [Related]  

  • 35. 18-Fluorine fluorodeoxyglucose positron emission tomography for the diagnosis of infection in the postoperative spine.
    De Winter F; Gemmel F; Van De Wiele C; Poffijn B; Uyttendaele D; Dierckx R
    Spine (Phila Pa 1976); 2003 Jun; 28(12):1314-9. PubMed ID: 12811277
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The prognostic value of positron emission tomography/computed tomography in rheumatoid arthritis patients with methotrexate-associated lymphoproliferative disorders.
    Takanashi S; Nakazato T; Aisa Y; Ito C; Arakaki H; Osada Y; Hirano M; Mori T
    Ann Hematol; 2018 Sep; 97(9):1611-1618. PubMed ID: 29713747
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Role of
    Dolci C; Ceppi L; Guerra L; Crivellaro C; Lamanna M; Adorni M; Elisei F; Bonazzi CM; Sina F; Fruscio R; Messa C
    Int J Gynecol Cancer; 2019 Oct; 29(8):1298-1303. PubMed ID: 31366569
    [TBL] [Abstract][Full Text] [Related]  

  • 38. FDG PET imaging in the evaluation of post-transplant lymphoproliferative disorder following renal transplantation.
    O'Conner AR; Franc BL
    Nucl Med Commun; 2005 Dec; 26(12):1107-11. PubMed ID: 16264358
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical value of fluorodeoxyglucose-positron emission tomography/computed tomography in differentiation of malignant mesothelioma from asbestos-related benign pleural disease: an observational pilot study.
    Yildirim H; Metintas M; Entok E; Ak G; Ak I; Dundar E; Erginel S
    J Thorac Oncol; 2009 Dec; 4(12):1480-4. PubMed ID: 19875971
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Utility of 18F-fluoro-deoxyglucose emission tomography/computed tomography fusion imaging (18F-FDG PET/CT) in combination with ultrasonography for axillary staging in primary breast cancer.
    Ueda S; Tsuda H; Asakawa H; Omata J; Fukatsu K; Kondo N; Kondo T; Hama Y; Tamura K; Ishida J; Abe Y; Mochizuki H
    BMC Cancer; 2008 Jun; 8():165. PubMed ID: 18541009
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.